LY-2090314

DB11913InvestigationalSmall molecule

Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

Mechanism: Pharmacologically active on Glycogen synthase kinase-3 beta and Glycogen synthase kinase-3 alpha
Curator reviewed
Formula / weight: C₂₈H₂₅FN₆O₃ · 512.545 g/mol (avg)
Code names: LY2090314

Resolves to

Compound

Structure

InChIKeyHRJWTAWVFDCTGO-UHFFFAOYSA-NSMILESFC1=CC2=C3N(CCN(C2)C(=O)N2CCCCC2)C=C(C3=C1)C1=C(C(=O)NC1=O)C1=CN=C2C=CC=CN12

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with LY-2090314, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.